Compare RDVT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDVT | ALLO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.9M | 539.4M |
| IPO Year | 2017 | 2018 |
| Metric | RDVT | ALLO |
|---|---|---|
| Price | $35.26 | $2.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $62.00 | $8.40 |
| AVG Volume (30 Days) | 107.6K | ★ 4.5M |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.00 | 34.09 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $90,252,000.00 | N/A |
| Revenue This Year | $15.06 | N/A |
| Revenue Next Year | $15.07 | $140,929.80 |
| P/E Ratio | $39.87 | ★ N/A |
| Revenue Growth | ★ 20.03 | N/A |
| 52 Week Low | $32.23 | $0.86 |
| 52 Week High | $64.14 | $2.80 |
| Indicator | RDVT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 49.90 |
| Support Level | N/A | $2.14 |
| Resistance Level | $52.43 | $2.76 |
| Average True Range (ATR) | 2.06 | 0.22 |
| MACD | -0.42 | -0.04 |
| Stochastic Oscillator | 6.28 | 30.30 |
Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.